Prellis Biologics has raised $8.7 million in a new round of equity financing, according to a recently posed SEC filing.
The San Francisco-based company is developing ultra-fast high-resolution holographic laser printing technology intended for use in creating human organs and tissues, according to its website.
Prellis Biologics offers a number of products based around vascularized tissue structures and extracellular matrices intended to grow human tissues and cells, according to the site.
A total of 11 anonymous investors participated in the round, with the first date of sale noted as having occurred on March 12.
The company is looking to raise an additional $475,000 in the round which would bring the total raised up to $9.2 million, according to the SEC filing.